hotspot -WSS

hotspot

author：entertainment 2025-10-01 00:47:05 - browse：5663

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Roche drug slashes death risk in early

WSS

The problems with dementia villages

Is there really a nursing shortage in the U.S.?

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Life sciences investors close nearly $6 billion in new funds

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

FDA clears Verve to begin U.S. study of gene

explore

hotspot

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Brain injuries and the importance of a second opinion

Psychedelics group wrestles with new pharma identity

Life sciences investors close nearly $6 billion in new funds

Alkermes shareholders re

Kidney transplant patients stopped immunosuppressants in trial

DIEP, the 'gold standard' of breast reconstruction, is under threat

Roche drug slashes death risk in early

BioMarin wins approval for gene therapy to treat hemophilia A

Roche drug slashes death risk in early

explore

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Smaller biotechs seek to piggyback on weight loss drug boom

Travis Kelce and the trap of celebrity vaccine endorsements

Bill would allow buprenorphine prescription for addiction via telehealth

STAT Readout Newsletter: Biotech news today

DeepMind touts AlphaFold's new skills as protein folding AI models face off

hotspot

hotspot

leisure time

explore